British regulator says AstraZeneca COVID shot clots rise to 168

Panorama of a city business district with office buildings and skyscrapers and superimposed data, charts and diagrams related to stock market, currency exchange and global finance. Blue line graphs with numbers and exchange rates, candlestick charts and financial figures fill the image with a glowing light. Sunset light.
imageStock Markets2 hours ago (Apr 22, 2021 19:25)

© Reuters. FILE PHOTO: COVID-19 vaccination at Newmarket Racecourse


By Alistair Smout

LONDON (Reuters) – Britain’s medicines regulator on Thursday said there had been 168 major blood clots following a dose of COVID-19 vaccine, a rate of 7.9 clots per million doses, a jump in incidence from the previous week’s figure.

This was up from the 100 cases reported last week, when the overall case incidence was 4.9 per million doses.

There has been scrutiny of the AstraZeneca (NASDAQ:AZN) vaccine on the issue of the very rare clots and some countries, including Britain, have recommended that only people over a certain age get the shot.

Adam Finn, Professor of Paediatrics at Bristol University, said the jump in reported cases was expected.

“Cases are being reported reliably and quickly but there are also cases that occurred previously now being recognised and reported as well,” Finn said.

“I would expect the true number of cases per million doses of vaccine to become clear fairly soon as these reports stabilise but it is already clear that it is going to remain a very rare event.”

There have been 21.2 million first doses of AstraZeneca’s shot given in Britain’s rollout, with all except one of the side effect case reports coming after a first dose. A total was not given for second doses administered.

There were 32 reported deaths from clots in total, compared to 22 reported last week, but the fatality rate of the reported clots dropped to 19% from 22%.

Britain has advised that under-30s receive an alternative to the AstraZeneca-Oxford vaccine, after the MHRA medicine regulator found there was evidence of a link to rare clots with low platelet levels.

Officials have emphasised the side effect is “vanishingly” rare and advised that most people still get the shots. The preference for under-30s to get a different shot is mainly informed by that age group’s low risk from COVID-19, combined with Britain’s low prevalence of infection.

That differs from several European countries such as France, which has decided to restrict use of AstraZeneca’s shot to people over 55.

“On the basis of this ongoing review, the advice remains that the benefits of the vaccine outweigh the risks in the majority of people,” the MHRA said on Thursday, reiterating its advice for the shot.

British regulator says AstraZeneca COVID shot clots rise to 168

Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All CFDs (stocks, indexes, futures) and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn`t bear any responsibility for any trading losses you might incur as a result of using this data.

Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.


Please enter your comment!
Please enter your name here